This Market Spotlight report covers the Hypogonadism market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, patent information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
Published: 09 September 2021
Number of pages:28
This Market Spotlight report covers the Hypogonadism market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, key upcoming and regulatory events, probability of success, patent information, epidemiology, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
The approved drugs in the hypogonadism space target androgen receptors, estrogen receptor alpha, and estrogen receptor beta. These are commonly administered via the transdermal route, with a smaller number of products being available in oral, intramuscular, intranasal, sublingual/oral transmucosal, subcutaneous, and topical formulations.
There are only three industry-sponsored drugs in active clinical development for hypogonadism, with one drug each in Phase II, Phase III, and the NDA/BLA phase.
Therapies in development for hypogonadism focus on targets such as androgen receptors, estrogen receptor alpha, estrogen receptor beta, and aromatase. These pipeline drugs are administered via the oral route.
Expected PDUFA dates for Tlando and Kyzatrex are the only high-impact upcoming events for drugs in the hypogonadism space. The overall likelihood of approval of a Phase I endocrine-other asset is 16.6%, and the average probability a drug advances from Phase III is 67.4%. Drugs, on average, take 10.2 years from Phase I to approval, compared to 9.8 years in the overall endocrine space.
There are almost equal proportions of clinical trials for hypogonadism across Phase I–IV, with 51% in Phase I–II, and 49% in Phase III–IV.
The US has a substantial lead in the number of hypogonadism clinical trials globally. The UK leads the major European markets, while India has the top spot in Asia.
Clinical trial activity in the hypogonadism space is dominated by completed trials. AbbVie has the highest number of completed clinical trials for hypogonadism, with eight trials.
AbbVie leads industry sponsors with the highest overall number of clinical trials for hypogonadism, followed by GlaxoSmithKline.
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
8 Treatment of hypogonadism in females
8 Treatment of hypogonadism in males
10 MARKETED DRUGS
14 PIPELINE DRUGS
18 KEY UPCOMING EVENTS
19 PROBABILITY OF SUCCESS
20 REVENUE OPPORTUNITY
22 CLINICAL TRIAL LANDSCAPE
23 Sponsors by status
24 Sponsors by phase
LIST OF FIGURES
14 Figure 1: Overview of pipeline drugs for hypogonadism in the US
14 Figure 2: Pipeline drugs for hypogonadism, by company
15 Figure 3: Pipeline drugs for hypogonadism, by drug type
15 Figure 4: Pipeline drugs for hypogonadism, by classification
18 Figure 5: Key upcoming events in hypogonadism
19 Figure 6: Probability of success in the endocrine-other pipeline
22 Figure 7: Clinical trials in hypogonadism
22 Figure 8: Top 10 drugs for clinical trials in hypogonadism
23 Figure 9: Top 10 companies for clinical trials in hypogonadism
23 Figure 10: Trial locations in hypogonadism
24 Figure 11: Hypogonadism trials status
25 Figure 12: Hypogonadism trials sponsors, by phase
LIST OF TABLES
11 Table 1: Marketed drugs for hypogonadism
16 Table 2: Pipeline drugs for hypogonadism in the US
20 Table 3: Historical global sales, by drug ($m), 2016–20
21 Table 4: Forecasted global sales, by drug ($m), 2021–25
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726